Double Blind Comparative Study of TAK-875

Diabetic Patients Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01585792
• Other study ID #: TAK-875/CPH-030
• Secondary ID: U1111-1129-7907J
• Status: Completed
• Phase: Phase 3
• First received: April 24, 2012
• Last updated: April 15, 2013
• Start date: May 2012
• Est. completion date: December 2012

Study information

• Verified date: April 2013
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• The participant is an outpatient.

• The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

• The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.

• The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Patients

Intervention

Drug:
• TAK-875

• TAK-875

• Glimepiride

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood glucose	Blood glucose	4 weeks	No